logo
ProjectOngoing

Patient Relevant Osteoarthritis endpoints using Big data Evaluation

Ongoing · Netherlands, United Kingdom, Germany, Finland, Spain, Denmark, France, Sweden, Belgium, Ireland, Austria, Estonia, Norway, Switzerland, United States

Source: EU Funding & Tenders Portal

Osteoarthritis (OA) causes pain, disability, and economic burden for 500+ million people. Developing disease modifying osteoarthritis drugs is crucial, but challenging due to disease heterogeneity, slow progression, and regulatory issues. The PROBE consortium addresses these challenges by integrating diverse and disparate datasets, combined with all necessary expertise, creating a federated databa

Status
Under Construction
Sector
Education, Hospital, Government
Location
Netherlands, United Kingdom, Germany, Finland, Spain, Denmark, France, Sweden, Belgium, Ireland, Austria, Estonia, Norway, Switzerland, United States
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Patient Relevant Osteoarthritis endpoints using Big data Evaluation

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “Patient Relevant Osteoarthritis endpoints using Big data Evaluation” is an infrastructure initiative in the Education sector, located in Netherlands, United Kingdom, Germany, Finland, Spain, Denmark, France, Sweden, Belgium, Ireland, Austria, Estonia, Norway, Switzerland, United States. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Sponsoring Agency

Status

Original status

ongoing

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Osteoarthritis (OA) causes pain, disability, and economic burden for 500+ million people. Developing disease modifying osteoarthritis drugs is crucial, but challenging due to disease heterogeneity, slow progression, and regulatory issues. The PROBE consortium addresses these challenges by integrating diverse and disparate datasets, combined with all necessary expertise, creating a federated database network. PROBE will unite critical mass in OA data and multidisciplinary disease specific expertise, federated infrastructure experts, AI and ML expertise, data privacy and ethics experts, health economics and outcome researchers, and indispensable patient, HTA, and regulatory perspectives experts, to achieve significant advancements in trial designs and tools for shared decision making. The overarching aim of PROBE is to deliver data-driven opportunities for the treatment of OA, through enhancements in patient stratification, predicative modelling, patient/caregiver interface decision tools and clinical trial design. Outcomes include a federated and regulatory compliant database network of disparate OA data for powerful, innovative big data methodology. In close collaboration with key stakeholders, we will also provide novel multimodal and relevant endpoints to test emerging treatments, models to enable stratified medicine and support shared prognostic and treatment decision-making and Health Technology Assessment. The impact of PROBE encompasses the foundation for advanced clinical trial design, predictive models for OA progression, novel endpoints, stratified patient subgroups and the ability to target treatments to patients’ needs and preferences, and tools that enable specific functional measurements and reflect real-life treatment benefits. The PROBE consortium holds the potential to reshape the landscape of OA clinical trials/treatment and ultimately improve the lives of all people affected by OA.

Location

Country

Netherlands, United Kingdom, Germany, Finland, Spain, Denmark, France, Sweden, Belgium, Ireland, Austria, Estonia, Norway, Switzerland, United States

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Education, Hospital, Government

Article published date

2026-01-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project